Based on the distinctive traits of mesenchymal stem cells (MSC), it has been postulated that these cells may play a critical role in regenerative medicine. In addition to the participation of MSC in the repair of mesodermal-derived tissues (bone, cartilage), robust data have suggested that MSC may also play a reparative role in conditions involving damage of cells of ectodermal origin. Several preclinical studies have put forward the concept that MSC therapy may represent an option for the treatment of several neurological disorders and injuries, including amyotrophic lateral sclerosis (ALS). In this review, Carolina Allers, Janet A Jones, Gabriel P Lasala and José J Minguell examine the most representative biomedical literature dealing with cellular, molecular and preclinical studies that have strengthened the notion that cellular therapy represents a feasible and robust option for the treatment of ALS.
"For ALS patients having no illusion of a panacea, the opening of that clinical trial symbolized the awaited right of hope"
Allers C, Jones JA, Lasala GP, Minguell JJ. Mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis: signals for hope? Regen. Med. 9(5), 637–647 (2014)